Scientific Reports · 2021 · 14 citations · 24 references
Life SciencesEndocrinologyPharmacologyCell SignalingMetabolic RegulationSignal TransductionG Protein-coupled Receptor SignalingGlucagon Signaling In MetabolismMetabolic SignalingReceptor PharmacologyReceptor PhysiologyWeight ManagementBody Weight RegulationGlucagon Receptor AgonismGlucagon Receptor AgonistsGlucagon Receptor PharmacologyGlucagon Receptor SignalingInterindividual VariationReceptor Binding SpecificityReceptor Subtype Specificity
Glucagon receptor agonists show promise as components of next generation metabolic syndrome pharmacotherapies. However, the biology of glucagon action is complex, controversial, and likely context dependent. As such, a better understanding of chronic glucagon receptor (GCGR) agonism is essential to identify and mitigate potential clinical side-effects. Herein we present a novel, long-acting glucagon analogue (GCG104) with high receptor-specificity and potent in vivo action. It has allowed us to make two important observations about the biology of sustained GCGR agonism. First, it causes weight loss in mice by direct receptor signalling at the level of the liver. Second, subtle changes in GCG104-sensitivity, possibly due to interindividual variation, may be sufficient to alter its effects on metabolic parameters. Together, these findings confirm the liver as a principal target for glucagon-mediated weight loss and provide new insights into the biology of glucagon analogues.
24
Tissue-based map of the human proteome
Mathias Uhlén, Linn Fagerberg, Björn M. Hallström et al. · Science · 2015 · 15.9K citations · Full text
Phil Ambery, Victoria E R Parker, Michael Stümvoll et al. · The Lancet · 2018 · 295 citations
Glucose Metabolism In Vivo in Four Commonly Used Inbred Mouse Strains
Eric D. Berglund, Candice Y. Li, Greg Poffenberger et al. · Diabetes · 2008 · 270 citations · Full text
Medicine, Endocrinology, Diabetology +10